Authorized purpose: Provides passive worklist prioritization for compatible FFDM and DBT screening mammograms.
Clinical role
Triage or notification support
Images and patients
Mammography/DBT · Breast
Key limitation
Keep in mind: Passive notification only, with no diagnostic information beyond triage; not a replacement for image review or standalone decision-making and cases remain on the worklist.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Provides passive worklist prioritization for compatible FFDM and DBT screening mammograms.
Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast Input: DICOM files from one FFDM or DBT screening study, compatible with specified Hologic mammography equipment.
Who uses it?Intended users: Interpreting radiologists.
What does the software produce?Output: A Saige-Q suspicion code to PACS, EPR, RIS, or workstation; suspicious studies also receive an informational compressed preview.
What is its most important limitation?Key limitation: Passive notification only, with no diagnostic information beyond triage; not a replacement for image review or standalone decision-making and cases remain on the worklist.
Clinical takeaway. Clinical role: Provides passive worklist prioritization for compatible FFDM and DBT screening mammograms.
Evidence takeaway. Evidence from the reviewed source record: Retrospective blinded multicenter FFDM study of 501 malignant and 832 normal cases and DBT study of 517 malignant and 1,011 normal cases reported AUC 0.966 and 0.985 respectively; no one global accuracy applies.
Purpose
Provides passive worklist prioritization for compatible FFDM and DBT screening mammograms.
Exact FDA submission
Checked 2026-09-15
Clinical-use display mirrors the exact FDA-supported purpose reconciled in this remediation finding.
Passive notification only, with no diagnostic information beyond triage; not a replacement for image review or standalone decision-making and cases remain on the worklist.
Retrospective blinded multicenter FFDM study of 501 malignant and 832 normal cases and DBT study of 517 malignant and 1,011 normal cases reported AUC 0.966 and 0.985 respectively; no one global accuracy applies.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
Retrospective blinded multicenter FFDM study of 501 malignant and 832 normal cases and DBT study of 517 malignant and 1,011 normal cases reported AUC 0.966 and 0.985 respectively; no one global accuracy applies.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Saige-Q regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K203517
Samplen=2861
Sites14
IndependenceIndependence not established
K203517
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K203517. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Deployment category preserved from the prior exact-submission review; hosting region, data flow, and current commercial configuration still require vendor confirmation.
The exact-submission ACR model card explicitly references DICOM, PACS, and RIS in the described input, output, or workflow; exact interfaces, versions, and local compatibility require confirmation.
Exact FDA submission
Checked 2026-09-01
Interoperability terms explicitly reported in the exact-submission ACR model card; interface versions and local compatibility still require confirmation.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
28Fields reviewed
10Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-09 - Exact FDA submission
No public price or quote for the exact K203517 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-09 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-09 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-09 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-09 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.
Authorized purpose: Prioritizes suspicious screening DBT examinations for MQSA interpreting physicians; every examination remains subject to full physician review.
The VinDr-Mammo is a passive notification for prioritization-only, a parallel- workflow software tool used by MQSA qualified interpreting physicians to prioritize patients with suspicious findings in the medical care environment. VinDr-Mammo utilizes an artificial intelligence algorithm to analyze 2D FFDM screening mammograms and flags those that are suggestive of the presence of at least one suspicious finding at the exam- level. VinDr-Mammo produces an exam-level output to a PACS/Workstation for flagging the suspicious case and allows worklist prioritization. MQSA qualified interpreting physicians are responsible for reviewing each exam on a display approved for use in mammography, according to the current standard of care. VinDr-Mammo device is limited to the categorization of exams, does not provide any diagnostic information beyond triage and prioritization, does not remove images from the interpreting physician’s worklist, and should not be used in lieu of full patient evaluation, or relied upon to make or confirm diagnosis. The VinDr-Mammo device is intended for use with complete 2D FFDM mammography exams acquired using validated FFDM systems only.